Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Maxinovel Raises $14 Million for Novel Small Molecule Portfolio

publication date: Oct 24, 2022

Guangzhou Maxinovel Pharmaceuticals closed a $14 million Series C+ round to support its portfolio of eight small molecule targeted and immunotherapy candidates. Maxinovel’s lead product is a small molecule PD-L1 inhibitor that matched the efficacy of Durvalumab in a human PD-1 knock-in mice model. The company is developing products for hematological tumors, solid tumors and autoimmune diseases using its oral, radiotherapy imaging and transdermal platforms. The C+ round funds were raised from LAPAM Capital, Zhongxin Capital and Deyi Runrong Venture Capital. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital